Chief Medical Officer, Oblenio Bio

Company Overview 

Oblenio Bio is focused on achieving the significant potential of T-cell engagers as a novel therapeutic approach that addresses underlying disease pathophysiology and achieves immune reset. An Aditum Bio company, Oblenio Bio was formed in November 2024 following the exclusive option to license LBL-051, a first-in-class T-cell engager antibody that targets both CD19 and BCMA in autoimmune disorders.   

Oblenio Bio is a portfolio company of Aditum Bio.

About Aditum Bio: Aditum Bio’s mission is to provide access to medicines to patients in need.  Co-founded by industry veterans Joe Jimenez, former CEO of Novartis and Mark Fishman, former President of the Novartis Institutes for Biomedical Research, the firm in-licenses promising therapies and advances them into Phase 1 and Phase 2 clinical studies to enable proof of concept.   The firm focuses on the translational phase of medicine to generate data that can support full clinical development, and eventual market launch, to reach patients in need.

In keeping with the Aditum Bio team culture, this position will be hybrid, with two days per week in person in Cambridge, MA.   Potential flexibility on this arrangement.

 

Position Summary

The Chief Medical Officer, Oblenio Bio will serve as a key member of Oblenio Bio’s leadership team, responsible for driving and overseeing the clinical development strategy and execution of Oblenio Bio’s pipeline, beginning with LBL-051, a differentiated trispecific T-cell engager. This physician-scientist will partner with Oblenio Bio’s CEO to shape the strategic direction of Oblenio Bio.

 

Position Responsibilities 

Lead Clinical Development Strategy

• Design fit for purpose Phase I and Phase II trials to enable rapid entry to clinic and proof of mechanism. Accountable for progress toward key clinical milestones as both a leader and hands-on contributor, collaborating as a member of the cross-functional translational and development team.
• Lead implementation of a clinical development program in support of the overall product development plan, based on strong medical and scientific principles, including understanding of relevant translational models, biomarkers and immunological principles as well as knowledge of the evolving competitive landscape, clinical operations, compliance and regulatory requirements.
• Operate effectively in both high-level, long-term strategic planning and at the operational level, ensuring day-to-day progress of trials.
• Collaborate with CEO to clearly and credibly communicate to external stakeholders the clinical strategy and product differentiation in a competitive field as a key part of the value proposition of Oblenio Bio

 

Guide and Collaborate on Pre-Clinical Activities

• Provide input to cross functional program teams on pre-clinical activities that will best support clinical development (e.g., pharmacology models, clinical pharmacology, biomarker development)

 

Clinical Execution

• Ensure the high quality execution on planned trials with the goal of producing compelling clinical data – through a combination of hands-on delivery and oversight of team members and CROs.  Focus onkey clinical pillars such as safety, monitoring, and site/investigator relations  in the pursuit of a high-quality therapy reflective of the target product profile.

 

Function Leadership

• May be responsible for identifying and managing full-time or contracted team members to ensure adequate resourcing of Oblenio Bio’s medical function.
• Provide mentorship and professional development opportunities for team members. Establish clear goals and expectations, and regularly assess team performance to ensure objectives are met.
• Collaborate closely with cross-functional teams, including nonclinical development, manufacturing, regulatory affairs, and clinical operations, to ensure progress toward clinical milestones.

 

Qualifications 

• MD or MD/PhD with deep experience working on early stage development programs and design (pre-IND, IND, Phase 1 and 2)
• Experience in immunology and inflammation preferred.
• Minimum of 10 years of experience in clinical development, with at least 5 years in a pharmaceutical or biotech company setting. Start-up experience as CMO is a plus.
• Demonstrated ability to effectively run global clinical programs with minimal direction
• Extensive knowledge of clinical trial methodology, regulatory and compliance requirements governing clinical trials, and experience in development of clinical strategy and the design of study protocols
• Proven leadership